Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PACB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CEO (new) — Christian Henry stepped down as CEO after six years, though he remains on the Board and will serve as business advisor through year-end 2026 to facilitate transition.
PacBio names COO Mark Van Oene CEO, cuts 8% of workforce to save $30M-$40M annually
Filed August 5, 2026 · Period ending July 30, 2026 · ~2 min read
Key Changes
-
high
Mark Van Oene appointed President and CEO effective Aug 5, 2026, succeeding Christian Henry who stepped down after six years but remains on Board through year-end transition.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
Board approved restructuring plan reducing workforce by ~40 employees (8% of headcount) to cut annualized operating expenses by $30M-$40M by end of 2027; expects $2M in Q3 2026 severance charges.
Item 2.05 — Costs Associated with Exit or Disposal Activities verify on EDGAR → -
high
Q2 2026 revenue of $39.0M essentially flat year-over-year; non-GAAP gross margin compressed to 36% from 38% on higher compute costs and lower Revio pricing; full-year 2026 revenue guidance $155M-$165M.
Exhibit 99.1 view on EDGAR → -
medium
Launched SPRQ-Nx chemistry globally at $345 per genome with enhanced methylation detection and AI-powered consensus algorithm; began sequencing for Basecamp Research, largest population-scale program to date.
Exhibit 99.1 view on EDGAR → -
medium
Van Oene compensation: $743K base salary, 100% target bonus, $2.25M equity grants ($1.69M stock option, $562.5K RSUs); 18-month change-in-control severance. Henry receives $12.9K monthly through Dec 2026, then $1.16M separation payment.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Pacific Biosciences executed a dual leadership and cost restructuring on July 30, 2026. The Board appointed COO Mark Van Oene as President and CEO effective August 5, replacing Christian Henry, who stepped down after six years but remains on the Board through a year-end advisory transition.
Van Oene joined PacBio in 2021 and has led operational execution, commercial strategy, and AI-related product development; the Board cited his experience scaling clinical diagnostics businesses as aligned with PacBio's strategic focus.
Simultaneously, the Board approved an 8% workforce reduction (approximately 40 employees) expected to cut annualized operating expenses by $30 million to $40 million by end of 2027, with $2 million in Q3 2026 severance charges. The restructuring aims to align resources with strategic priorities as the company navigates flat revenue growth and margin compression. Q2 2026 results showed $39.0 million revenue (essentially flat year-over-year), with consumables growing to $20.1 million but instrument revenue declining to $12.8 million. Non-GAAP gross margin compressed to 36% from 38% on higher compute costs, Vega manufacturing transition expenses, and lower Revio pricing on multi-system deals. The company guided full-year 2026 revenue to $155 million-$165 million. PacBio launched SPRQ-Nx chemistry globally at $345 per genome and began sequencing for Basecamp Research, its largest population-scale program. The CEO transition during a cost-reduction cycle and margin pressure warrants attention to execution continuity and whether the restructuring delivers the targeted savings while Van Oene advances the clinical and AI strategy the Board emphasized in his appointment.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Pacific Biosciences announced Q2 2026 financial results on August 5, 2026.
Added in current filing · verify on EDGAR →
On August 5, 2026, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its second fiscal quarter ended June 30, 2026.
The company disclosed its financial results for the second fiscal quarter ended June 30, 2026. The 8-K references a press release (Exhibit 99.1) containing the detailed announcement, but the filing body does not provide specific financial figures such as revenue, earnings per share, or guidance.
Event · Item 2.05 — Costs Associated with Exit or Disposal Activities
Item 2.05 — Costs Associated with Exit or Disposal Activities filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 30, 2026, the Board of Directors (the “Board”) of the Company approved a restructuring plan to continue to better align the Company’s organizational structure and resources with its strategic initiatives. The restructuring includes operating expense reductions and a reduction in force (the “Reduction in Force”). These restructuring actions are expected to result in a workforce reduction of approximately 40 employees, or approximately 8% of the Company's workforce, as the Company aligns its organizational structure with its strategic priorities.
The Board approved a restructuring plan on July 30, 2026, that will reduce the workforce by approximately 40 employees, representing about 8% of total headcount. The plan aims to align the company's organizational structure and resources with its strategic initiatives.
Added in current filing · verify on EDGAR →
The Company estimates that it will incur aggregate pre-tax charges of approximately $2.0 million in connection with the Reduction in Force, primarily consisting of severance payments, employee benefits, outplacement services and related costs. The Company expects that the Reduction in Force will be completed and that these charges will be incurred in the third quarter of 2026.
The company expects to incur approximately $2.0 million in pre-tax restructuring charges during the third quarter of 2026, primarily for severance payments, employee benefits, outplacement services, and related costs. The workforce reduction is expected to be completed in Q3 2026.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Under the New Severance Agreement, in the event of a termination of his employment without cause, or his resignation from such employment for good reason, each in connection with a change in control, Mr. Van Oene will receive a lump sum cash payment equal to 18 months of his base salary and Company-paid premiums for continuation coverage pursuant to COBRA for up to 18 months (each increased from 12 months).
Van Oene's severance agreement provides enhanced change-in-control protections: 18 months of base salary and COBRA coverage if terminated without cause or he resigns for good reason in connection with a change in control, increased from the prior 12-month standard.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
PacBio reported total revenue of $39.0 million for Q2 2026, essentially flat versus $39.8 million in Q2 2025. Consumable revenue grew to $20.1 million from $18.9 million year-over-year, while instrument revenue declined to $12.8 million from $14.2 million. The company placed 20 Revio systems (up from 15 in Q2 2025) and 26 Vega systems (down from 38 in Q2 2025). Annualized Revio pull-through per system was approximately $202,000, down from approximately $219,000 in the prior-year quarter.
Added in current filing · view on EDGAR →
Non-GAAP gross margin was 36% for the second quarter of 2026 compared to 38% for the second quarter of 2025. The decline in non-GAAP gross margin was primarily driven by higher compute and memory costs, Vega manufacturing transition costs, and lower Revio average selling prices associated with strategic multi-system customer placements.
Non-GAAP gross margin compressed to 36% in Q2 2026 from 38% in Q2 2025, driven by higher compute and memory costs, Vega manufacturing transition costs, and lower Revio pricing on multi-system deals. Non-GAAP net loss was $41.9 million ($0.14 per share) versus $40.0 million ($0.13 per share) in Q2 2025. GAAP net loss was $44.7 million ($0.14 per share) versus $41.9 million ($0.14 per share) in the prior-year quarter.
Added in current filing · view on EDGAR →
PacBio expects revenue for the full year 2026 to be in the range of $155 million to $165 million.
The company issued full-year 2026 revenue guidance of $155 million to $165 million. With $76.2 million in revenue for the first half of 2026, the guidance implies second-half revenue of approximately $78.8 million to $88.8 million.
Added in current filing · view on EDGAR →
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection and DeepConsensus, an AI-powered consensus algorithm co-developed with Google
PacBio launched its SPRQ-Nx chemistry globally, offering whole genome sequencing at a $345 list price per genome with enhanced methylation detection and an AI-powered consensus algorithm developed with Google. This represents a key product advancement aimed at improving sequencing economics and capabilities.
Added in current filing · view on EDGAR →
Commenced sequencing and sample delivery for Basecamp Research, a frontier AI lab for therapeutic design, marking a significant operational milestone for PacBio's largest population-scale program to date
PacBio began sequencing and sample delivery for Basecamp Research, described as the company's largest population-scale program to date. This milestone demonstrates progress in scaling commercial operations for large-scale genomics projects.
Event · Exhibit 99.2
Added in current filing · view on EDGAR →
Mr. Van Oene joined PacBio in 2021 as Chief Operating Officer and has played a central role in advancing the company's operational execution, commercial strategy, product development roadmap and clinical application development as well as leading AI-related product improvements and collaborations. During his tenure, he has worked closely with the executive leadership team and Board of Directors to strengthen PacBio's position as a leader in long-read sequencing and to support PacBio’s strategy to expand adoption across research and future clinical applications.
Van Oene joined PacBio in 2021 as COO and has been central to operational execution, commercial strategy, product development, clinical applications, and AI-related product improvements. He has worked closely with leadership and the Board to strengthen PacBio's long-read sequencing position and expand adoption in research and clinical applications.
Added in current filing · view on EDGAR →
"Mark is an accomplished leader with deep experience building and scaling global life sciences and clinical diagnostic businesses, which has become an increasing focus of PacBio’s long-term strategy," said John Milligan, Ph.D., Chair of PacBio's Board of Directors. "Over the past several years, he has become an integral member of PacBio's leadership team and has helped shape our strategic priorities, strengthen our operational capabilities, and position the company for its next phase of growth, particularly with respect to AI-enabled product solutions and larger-scale AI and clinical related collaborations. The Board conducted a thoughtful succession planning process and unanimously concluded that Mark is the right leader to build on PacBio's strong foundation and drive long-term value creation for our customers, employees, and stockholders."
Board Chair John Milligan stated that Van Oene has deep experience in life sciences and clinical diagnostics, which aligns with PacBio's increasing strategic focus. The Board conducted a succession planning process and unanimously concluded Van Oene is the right leader to drive growth, particularly in AI-enabled products and clinical collaborations, and to create long-term value for stakeholders.
Added in current filing · view on EDGAR →
"On behalf of the Board, I also want to express our sincere gratitude to Christian for his outstanding leadership and many contributions to PacBio. During his tenure, Christian guided the company through a period of significant transformation, including expanding our product portfolio, strengthening our commercial organization, advancing our technology leadership, and positioning PacBio to pursue substantial long-term growth opportunities, especially in clinical and AI-related markets. We thank him for his unwavering commitment to PacBio and wish him continued success."
The Board thanked Christian Henry for his leadership during a period of significant transformation. Under his tenure, PacBio expanded its product portfolio, strengthened its commercial organization, advanced technology leadership, and positioned the company for long-term growth in clinical and AI-related markets.
Added in current filing · view on EDGAR →
"As we look ahead, we remain focused on delivering innovative sequencing solutions that enable our customers to answer some of biology's most important questions, expanding adoption of HiFi sequencing worldwide, executing with operational excellence, increasing our support of the clinical and diagnostics markets, and playing a leading role in developing AI-related HiFi sequencing solutions and databases, all as part of our continuing effort to create long-term value for our stockholders."
Van Oene outlined strategic priorities including delivering innovative sequencing solutions, expanding HiFi sequencing adoption worldwide, operational excellence, increasing support for clinical and diagnostics markets, and developing AI-related HiFi sequencing solutions and databases to create long-term stockholder value.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 6, 2026 · How we verify